方法：收集2014-04/2015-06我院收治的42例72眼糖尿病黄斑水肿患者为研究对象，将患者随机分为观察组与对照组，观察组给予雷珠单抗联合激光光凝治疗，对照组仅给予激光光凝治疗，对比分析两组患者黄斑水肿消退情况、黄斑中心凹视网膜厚度变化情况及视力提高情况。

结果：观察组黄斑水肿治疗总有效率为94%，对照组黄斑水肿治疗总有效率为78%，两组数据对比差异有统计学意义(P<0.05)； 治疗前，观察组患者黄斑中心凹视网膜厚度为486.58±85.26μm，对照组患者黄斑中心凹视网膜厚度为479.61±83.37μm，数据无统计学差异(P>0.05)； 治疗3mo后，观察组患者黄斑中心凹视网膜厚度为315.85±43.7μm，对照组患者黄斑中心凹视网膜厚度为418.85±46.97μm； 治疗6mo后，观察组患者黄斑中心凹视网膜厚度为245.58±25.67μm，对照组患者黄斑中心凹视网膜厚度为369.85±36.48μm，数据差异有统计学意义(P<0.05)； 观察组视力提高率为78%，对照组视力提高率为50%，数据差异有统计学意义(P<0.05)。

结论：糖尿病性黄斑水肿患者采用抗VEGF药物联合激光光凝治疗的临床效果显著，建议在临床上推广。

METHODS: Forty-two cases(72 eyes)of patients with diabetic macular edema collected from April 2014 to June 2015 in our hospital were randomly divided into observation group and control group. The observation group was given ranibizumab with laser photocoagulation therapy, and the control group was only given laser photocoagulation treatment. Macular edema subsiding, macular fovea retinal thickness change and vision improvement were compared between the two groups.

RESULTS: The total effective rate of the observation group was 94%, that of the control group was 78%, and the difference between the two groups was statistically significant(P<0.05). Before the treatment, macular foveal retinal thickness of the observation group was 486.58±85.26μm, that of the control group was 479.61±83.37μm, and the difference between the two groups was not statistically significant(P>0.05). At 3mo after treatments, the macular fovea retinal thickness of the observation group was 315.85±43.7μm that of the control group was 418.85±46.97μm. At 6mo after treatments, the macular fovea retinal thickness of the observation group and the control group was 245.58±25.67 and 369.85±36.48μm respectively, and the difference between the two groups was statistically significant(P<0.05). The vision improvement rates of the observation group and the control group were 78% and 50% respectively, and the difference between the two groups was statistically significant(P<0.05).

CONCLUSION: The treatment effect of ranibizumab with laser photocoagulation therapy for diabetic macular edema is remarkable, and recommended in clinical promotion.